WE ARE LOOKING FOR A MECHATRONICS ENGINEER

At Evosep, we are a small but very dedicated team with a long history in the nanoLC and proteomics community. We value an informal and constructive tone both internally and when working with our users. We are not perfect (and neither are you) but we enjoy the quest for high performance (and so should you).

The company is headquartered in Denmark, but our customers are evenly split between Europe and North America.

We are looking to extend our team with a Mechatronics Engineer based out of our Odense office who can support production and participate in research and development projects.

Responsibilities

- Spearheading development and support of robotic production of Evotips
- Contributing to overall mechanical and electrical design efforts in ongoing engineering projects.
- Working directly with suppliers and external partners to define engineering requirements and have mechatronics components designed and made.
- Keeping technical documentation and systems drawings etc up-to-date as well as training colleagues in systems use when necessary.

Qualifications

- At least a B.Sc. in mechanical, robotics, electrical engineering, or a related field.
- Strong understanding of mechanical and electrical engineering principles and fundamentals
- Understanding of, and preferably experienced in, developing software for automation tasks.
- Competence and experience in translating design requirements to engineering specifications (technical drawings, materials, tolerances)
- Excellent communication and "people" skills are essential. This goes for both writing and presenting skills, as well as listening and interaction skills in general.

If you are interested in learning more or want to submit an application, please contact CEO Christian Ravnsborg at cr@evosep.com or phone +45 26 33 20 21.

*Evosep aims to improve quality of life and patient care
by radically innovating protein based clinical diagnostics.
We will make sample preparation and separation for
MS analysis 10 times faster and 100 times more robust
in order to enable truly large cohort studies and
provide the foundation for precision medicine.*